Have a feature idea you'd love to see implemented?
Let us know!
ARWR Arrowhead Pharmaceuticals Inc
Price (delayed)
$18.28
Market cap
$2.27B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.66
Enterprise value
$2.32B
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger
Highlights
The net income has dropped by 197% year-on-year and by 14% since the previous quarter
ARWR's EPS has plunged by 174% YoY and by 10% from the previous quarter
Key stats
What are the main financial stats of ARWR
Market
Valuations
Earnings
Shares outstanding
124.32M
Market cap
$2.27B
Enterprise value
$2.32B
Price to book (P/B)
6.87
Price to sales (P/S)
115.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
118.14
Revenue
$19.65M
EBIT
-$516.96M
EBITDA
-$499.53M
Free cash flow
-$531.98M
Per share
Balance sheet
Liquidity
EPS
-$4.66
Free cash flow per share
-$4.28
Book value per share
$2.66
Revenue per share
$0.16
TBVPS
$7.04
Total assets
$883.76M
Total liabilities
$544.79M
Debt
$118.09M
Equity
$330.55M
Working capital
$353.35M
Debt to equity
0.36
Current ratio
4.65
Quick ratio
4.52
Net debt/EBITDA
-0.1
Margins
Efficiency
Dividend
EBITDA margin
-2,542.4%
Gross margin
100%
Net margin
-2,741.4%
Operating margin
-2,785.1%
Return on assets
-66.7%
Return on equity
-172.9%
Return on invested capital
-69.7%
Return on capital employed
-65.7%
Return on sales
-2,631.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARWR stock price
How has the Arrowhead Pharmaceuticals stock price performed over time
Intraday
-2.3%
1 week
-14.62%
1 month
-10.79%
1 year
-35.57%
YTD
-40.26%
QTD
-5.63%
Financial performance
How have Arrowhead Pharmaceuticals's revenue and profit performed over time
Revenue
$19.65M
Gross profit
$19.65M
Operating income
-$547.21M
Net income
-$538.64M
Gross margin
100%
Net margin
-2,741.4%
The net income has dropped by 197% year-on-year and by 14% since the previous quarter
The operating margin has dropped by 109% since the previous quarter
Arrowhead Pharmaceuticals's net margin has shrunk by 107% QoQ
The gross profit has shrunk by 92% YoY and by 45% QoQ
Growth
What is Arrowhead Pharmaceuticals's growth rate over time
Valuation
What is Arrowhead Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.87
P/S
115.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
118.14
ARWR's EPS has plunged by 174% YoY and by 10% from the previous quarter
The price to book (P/B) is 41% lower than the 5-year quarterly average of 12.0 and 41% lower than the last 4 quarters average of 12.0
The equity has contracted by 32% from the previous quarter and by 9% YoY
The price to sales (P/S) is 157% more than the 5-year quarterly average of 46.1 and 61% more than the last 4 quarters average of 73.4
The company's revenue has shrunk by 92% YoY and by 45% QoQ
Efficiency
How efficient is Arrowhead Pharmaceuticals business performance
Arrowhead Pharmaceuticals's return on invested capital has shrunk by 175% YoY and by 10% QoQ
ARWR's ROS has plunged by 108% from the previous quarter
The company's return on equity fell by 18% QoQ
The company's return on assets fell by 11% QoQ
Dividends
What is ARWR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARWR.
Financial health
How did Arrowhead Pharmaceuticals financials performed over time
ARWR's total assets is 62% higher than its total liabilities
The quick ratio has decreased by 44% from the previous quarter and by 30% YoY
The company's current ratio fell by 44% QoQ and by 30% YoY
Arrowhead Pharmaceuticals's debt is 64% lower than its equity
The debt to equity has soared by 57% YoY and by 44% from the previous quarter
Arrowhead Pharmaceuticals's debt has increased by 43% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.